23andMe_Logo_grey.png
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
June 28, 2024 07:00 ET | 23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in...
Alumis.png
Alumis Announces Pricing of Initial Public Offering
June 27, 2024 23:57 ET | Alumis Inc.
Alumis, a clinical-stage biopharmaceutical company developing oral therapies for immune mediated diseases, announces pricing of initial public offering
blue-mountain-logo-blue 1 1.png
Blue Mountain and Zifo, Global Leaders in Life Sciences Pharmaceutical Manufacturing, Announce Strategic Partnership to Revolutionize Enterprise Asset Management
June 27, 2024 09:00 ET | Blue Mountain
Blue Mountain and Zifo announce a partnership to enhance efficiency and innovation in the life sciences sector, offering advanced solutions for GMP.
Tourmaline_logo.jpg
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
June 27, 2024 08:05 ET | Tourmaline Bio, Inc.
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
QUOIN-COLORED-LOGO (1).png
Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome
June 27, 2024 08:00 ET | Quoin Pharmaceuticals, Inc.
Clinical site to be Opened in Saudi Arabia       Site Currently Treating Netherton Patients Who Are Eligible for Recruitment into Quoin Studies Experienced Local Clinical Research Organization Has...
Regeneron Logo.jpg
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
June 26, 2024 17:30 ET | Regeneron Pharmaceuticals, Inc.
Majority of patients in this age group with eosinophilic esophagitis (EoE) receiving Dupixent achieved histologic remission, with improvements sustained up to one year Dupixent is the first and only...
Tevogen Logo Notified.png
Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities
June 26, 2024 12:46 ET | Tevogen Bio Inc
This new registration statement does not relate to any previously undisclosed new issuances of dilutive securities.
NEW ATAI-Logo_Primary.png
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
June 26, 2024 07:00 ET | atai Life Sciences
NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance
June 25, 2024 09:20 ET | Cingulate Inc.
Twelve Required Registration Batches CompletedNew Drug Application Being Prepped for Submission KANSAS CITY, Kan., June 25, 2024 (GLOBE NEWSWIRE) -- In alignment with U.S. Food and Drug...
KBLB logo.jpg
Kraig Biocraft Laboratories Increases Spider Silk Production with Next Generation of Hybrid Eggs Completed
June 25, 2024 07:05 ET | Kraig Biocraft Laboratories
Kraig Labs (OTCQB: KBLB) expanded its production of spider silk with the creation of the next generation of BAM-1 hybrid